Alisha A. Alaimo Appointed SVP of Biogen’s US Therapeutic Operations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Biogen (BIIB) PT Raised to $285 at UBS Following Strong 2Q
July 26, 2017 8:44 AM EDTUBS raised its price target on Biogen (NASDAQ: BIIB) to $285.00 (from $270.00) while maintaining a Neutral rating following the company's 2Q. BIIB recorded a $284M top-line beat. EPS also came in ahead with a $0.53 beat.
Despite a strong 2Q print, the mid-to-long term outlook... More
